Morgan Stanley is out with a research report on Pharmasset, Inc. VRUS and is raising its price target to $206 from $175, and it has an Overweight rating on shares.
In a note to clients, Morgan Stanley writes, "PSI-7977, Pharmasset's key value driver, has demonstrated solid efficacy (interim and final) across HCV genotypes 1,2,3 in regimens both with and without PEG/ribavirin. This broad activity
and combinability creates many potential paths to market. We expect clarity on the G2/3 path, a faster approach vs. our base case, in 1H12 post-SVR data from Ph 2b G2/3 studies. Note: these paths are our assumptions, with the company not endorsing a specific one to date."
Shares of VRUS closed at $130.75 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in